(Q34194316)

English

Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited (English)

1 reference

Europe PubMed Central

31 July 2017

0 references

author name string

Lichtenberger LM

1

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

1 March 2001

1 reference

Europe PubMed Central

31 July 2017

Biochemical Pharmacology

1 reference

Europe PubMed Central

31 July 2017

61

1 reference

Europe PubMed Central

31 July 2017

631-637

1 reference

Europe PubMed Central

31 July 2017

6

1 reference

Europe PubMed Central

31 July 2017

Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986-1990

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Aspirin as an antiplatelet drug

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Aspirin and the Risk of Colorectal Cancer in Women

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Non-steroidal anti-inflammatory drugs and peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Prophylactic aspirin and risk of peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Gastric ulcer formation and cyclo-oxygenase inhibition in cat antrum follows parenteral administration of aspirin but not salicylate

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Mechanisms of acute and chronic intestinal inflammation induced by indomethacin

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Comparison of intravenous and intragastric aspirin in production of antral gastric ulcers in cats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Idiosyncracies of drug metabolism in cats. Effects on pharmacotherapeutics in feline practice

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

The conjugation of 1- and 2-naphthols and other phenols in the cat and pig

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Acute effect of systemic aspirin on gastric mucosa in man

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Failure of Intravenous Aspirin to Increase Gastrointestinal Blood Loss

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Mucosal adaptation to indomethacin induced gastric damage in man--studies on morphology, blood flow, and prostaglandin E2 metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Inhibition of both cyclooxygenase (COX)-1 and COX-2 is required for NSAID-induced erosion formation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Nitric oxide: a regulator of mucosal defense and injury

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Classical absorption theory and the development of gastric mucosal damage associated with the non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

The hydrophobic barrier properties of gastrointestinal mucus

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Role of surface-active phospholipids in gastric cytoprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Measurement of the surface hydrophobicity of human gastrointestinal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Phospholipid- and neutral lipid-containing organelles of rat gastroduodenal mucous cells. Possible origin of the hydrophobic mucosal lining

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Role of biliary phosphatidylcholine in bile acid protection and NSAID injury of the ileal mucosa in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900576-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-2952(00)00576-1

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34194316&oldid=1616229549"